DRUG: Bright Minds Biosciences Company Short-Term Debt

Symbol and logo of brand Bright Minds Bio (DRUG)

Bright Minds Biosciences (DRUG) focuses on developing innovative epilepsy treatments utilizing selective serotonin mechanisms within primary clinical trials. The price action chart demonstrates the asset's dynamics, where the key indicator is 0.00. The business relies on strict transport control of substances, ensuring absolute safety and reliability across all stages of drug delivery.

DRUG (Bright Minds Bio) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for Bright Minds Corp (DRUG)

- current quotes and average value forecast:
Price Chart Bright Minds Biosciences Inc.|DRUG - Fair Value Consensus
- market capitalization information:
Market Value Bright Minds Biosciences Inc.|DRUG - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Bright Minds Biosciences|DRUG - Book Capitalization|Market Cap to Net Assets Ratio brightmindsbio.com|DRUG - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Bright Minds Biosciences|DRUG - Long-Term Liabilities to Equity|Short-Term Debt to Equity Bright Minds Biosciences|DRUG - Company Total Debt Obligations|Debt to Book Value Bright Minds Biosciences Inc.|DRUG - Long-Term Debt|Company Short-Term Debts Bright Minds Biosciences|Quick Ratio brightmindsbio.com
- net income and valuation multiples indicators:
DRUG - Final Profit
Fundamental company analysis:Bright Minds Biosciences Inc. - DRUG
Mass-produced product of Bright Minds Biosciences

Liquidity at Bright Minds Biosciences (DRUG) determines the resilience of its R&D strategy. This metric aggregates all obligations maturing within twelve months, measuring the current debt load. It is critical for investors to assess the risk of cash flow gaps in the absence of commercial revenues. Amid the costly scaling of the pipeline, debt may grow faster than operational efficiency. By analyzing the short-term debt trend, one can evaluate the company's financial autonomy.

Main competitors

ALKS - Company Short-Term Debt|Company Short-Term Loans and Borrowings AVDL (Avadel Pharmaceuticals PLC)|atai Life Sciences Corp (ATAI) - Company Short-Term Debt|Company Current Liabilities GH Research Group|MNMD (Mind Medicine) - Company Short-Term Debts|Company Short-Term Debts compasspathways.com|Company Current Liabilities LBRX (LB Pharmaceuticals)|VNDA (Vanda Pharma) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Cybin CYBN|ANRO (Alto Neuroscience Corp) - Current Liabilities|NRXP - Company Short-Term Debt|Short-Term Debt Volume Cingulate Inc. CING|SILO (Silo Pharma) - Company Current Liabilities|Short-Term Debt China Pharma Holdings, Inc. (CPHI)|CMND (Clearmind Medicine Inc.) - Company Short-Term Debts|Company Current Liabilities Psyence Bio (PBM)|Company Short-Term Debts SPRC|SEEL (seelostherapeutics.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Virpax Pharmaceuticals, Inc. VRPX|Karuna Therapeutics Inc (KRTX) - Short-Term Debt